Search Results - "Hunold T"

Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.

Authors: Mocci, Giammarco Tursi, Antonio Scaldaferri, Franco et al.

Source: Journal of Clinical Medicine. Nov2025, Vol. 14 Issue 21, p7801. 19p.

Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study.

Authors: Maeyashiki, Chiaki Tamaki, Nobuharu Tanaka, Yuki et al.

Source: Journal of Clinical Medicine. Jul2026, Vol. 15 Issue 14, p5507. 12p.

Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team.

Authors: Hong, Seung Min Kim, Dong Hyun Bae, June Hwa et al.

Source: Intestinal Research. Jan2026, Vol. 24 Issue 1, p27-37. 11p.

Semen Discoloration Following Upadacitinib Therapy in Patients with Inflammatory Bowel Disease.

Authors: Lee, Jeong Hwa Cho, Hae Chang Cha, Jae Myung et al.

Source: Gut & Liver. Jul2026, Vol. 20 Issue 4, p704-708. 5p.

Cost calculation model of introducing Upadacitinib and Risankizumab for adult ulcerative colitis and Crohn's disease in the Kingdom of Saudi Arabia.

Authors: Mosli, Mahmoud H. Almutairdi, Abdulelah A. Alshahrani, Abdullah M. et al.

Source: Saudi Journal of Gastroenterology. Jan/Feb2026, Vol. 32 Issue 1, p66-78. 13p.

Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study.

Authors: Yerushalmy-Feler, Anat Spencer, Elizabeth A Dolinger, Michael T et al.

Source: Journal of Crohn's & Colitis. May2025, Vol. 19 Issue 5, p1-8. 8p.

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study.

Authors: Gilmore, Robert Fernandes, Richard Hartley, Imogen et al.

Source: Intestinal Research. Jul2025, Vol. 23 Issue 3, p347-357. 11p.

Rescue therapy with upadacitinib in severe Crohn's disease.

Authors: Caban, Miłosz Fabisiak, Adam Dudek, Patrycja et al.

Source: Gastroenterology Review / Przegląd Gastroenterologiczny. 2026, Vol. 21 Issue 2, p222-227. 6p.

Factors Influencing Clinical and Radiological Response in Perianal Disease: Results from a Real-World Cohort Treated with Anti-TNF Therapy.

Authors: Amiama Roig, Clara Suárez-Ferrer, Cristina Rueda García, José Luis et al.

Source: Journal of Clinical Medicine. Mar2026, Vol. 15 Issue 5, p2001. 15p.

Upadacitinib induction therapy in Crohn' s disease: a retrospective real-world study in biologic-refractory patients.

Authors: Fu, Xiaoyu Tu, Lei Fu, Yu et al.

Source: BMC Gastroenterology. 10/8/2025, Vol. 25 Issue 1, p1-11. 11p.

Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody.

Authors: Ikenouchi, Maiko Fukui, Hirokazu Yagi, Soichi et al.

Source: Intestinal Research. Oct2025, Vol. 23 Issue 4, p464-474. 11p.

Clinical characteristics of patients with difficult-to-treat ulcerative colitis: a nested case-control study using a Japanese claims database.

Authors: Matsuoka, Katsuyoshi Igarashi, Ataru Sato, Noriko et al.

Source: Intestinal Research. Jan2026, Vol. 24 Issue 1, p103-116. 14p.

Characteristics and long-term outcomes of children with perianal Crohn's disease.

Authors: Lin, Ching-Chun Takeuchi, Ichiro Shimizu, Hirotaka et al.

Source: Intestinal Research. Jan2026, Vol. 24 Issue 1, p164-173. 10p.

Efficacy of Upadacitinib Induction Treatment in Moderate-to-Severe Ulcerative Colitis Including Intestinal Ultrasound Assessment: A Multicenter, Real-World Observational Study.

Authors: Kaniewska, Magdalena Lewandowski, Konrad Krogulecki, Michał et al.

Source: Journal of Clinical Medicine. Mar2025, Vol. 14 Issue 5, p1695. 17p.

Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre Study.

Authors: Farkas, Bernadett Bessissow, Talat Limdi, Jimmy K. et al.

Source: Journal of Clinical Medicine. Dec2024, Vol. 13 Issue 24, p7804. 19p.

Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective.

Authors: Akiyama, Shintaro¹ (AUTHOR) akiyama@md.tsukuba.ac.jp

Source: Intestinal Research. Apr2026, Vol. 24 Issue 2, p197-207. 11p.

THE LEVELS OF INTERLEUKIN-6, SERUM CALPROTECTIN, AND HYPERSENSITIVE C-REACTIVE PROTEIN IN PATIENTS WITH CROHN'S DISEASE-RELATED MUCOSAL DAMAGE.

Alternate Title: NIVOI INTERLEU KINA-6, SERUMSKOG KALPROTEKTINA I VISOKOSENZITIVNOG C-REAKTIVNOG PROTEINA KOD PACIJENATA SA OŠTEĆENJEM SLUZOKOŽE POVEZANIM SA KRONOVOM BOLEŠĆU.

Authors: Zhang, Chuanshuo Zhou, Fengning Cao, Xiandong et al.

Source: Journal of Medical Biochemistry. Feb2026, Vol. 45 Issue 2, p310-316. 7p.

Effectiveness and safety of upadacitinib in refractory pediatric inflammatory bowel disease: A single-arm meta-analysis of observational studies.

Authors: Al Sarkhy, Ahmed A. AlZahrani, Alhanouf A. AlSunaidi, Afnan A.

Source: Saudi Journal of Gastroenterology. Jan/Feb2026, Vol. 32 Issue 1, p22-32. 11p.

Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib.

Authors: Park, Sarah St Pierre, Joelle Onajin, Oluwakemi et al.

Source: ACG Case Reports Journal. Oct2024, Vol. 11 Issue 10, p1-4. 4p.

A Case of Sweet Syndrome Complicating Ulcerative Colitis Treated With Upadacitinib.

Authors: Madabhushi, Sankirth Dixon, Sarah Dong, May et al.

Source: ACG Case Reports Journal. Nov2025, Vol. 12 Issue 11, p1-5. 5p.